Association of drug-serum protein adducts and anti-drug antibodies in dogs with sulphonamide hypersensitivity: A naturally occurring model of idiosyncratic drug toxicity

Clinical and Experimental Allergy

Volumn 36, Issue 7, 2006, Pages 907-915

  Lavergne, S N ^a   Danhof, R S ^a   Volkman, E M ^a   Trepanier, L A ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Anti drug antibody; Drug adduct; Drug hypersensitivity; Sulphamethoxazole

Indexed keywords

BIOLOGICAL MARKER; COTRIMAZINE; COTRIMOXAZOLE; DRUG ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NITROSO DERIVATIVE; ORMETOPRIM; SULFADIMETHOXINE; SULFAMETHOXAZOLE; SULFONAMIDE; SULFONAMIDE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOG; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG TOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE DEFICIENCY; IMMUNOBLOTTING; INFECTION PREVENTION; METABOLITE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODY SPECIFICITY; BLOOD PROTEINS; CROSS REACTIONS; DISEASE MODELS, ANIMAL; DOGS; DRUG HYPERSENSITIVITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGLOBULIN G; MALE; PROTEIN BINDING; SULFAMETHOXAZOLE; SULFONAMIDES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 33745671839     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2006.02506.x     Document Type: Article

References (45)

1. Bucher H, Griffith L, Guyatt G, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retovirol 1997; 15:104-14.
2. Greene CE. Infectious diseases of the dog and cat, 2nd edn. Philadelphia: W. B. Saunders, 1998.
3. Trepanier L, Danhof R, Toll J, Watrous D. Clinical findings in 40 dogs with hypersensitivity associated with potentiated sulfonamides. J Vet Intern Med 2003; 17:647-52.
4. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim anti-microbials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996; 15:9-50.
5. Reilly TP, Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol 2002; 2:307-15.
6. Cribb AE, Spielberg SP. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab Dispos 1990; 18:784-7.
7. Cribb AE, Spielberg SP. An in vitro investigation of predisposition to sulphonamide idiosyncratic toxicity in dogs. Vet Res Commun 1990; 14:241-52.
8. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11:969-88.
9. Svensson CK. Do arylhydroxylamine metabolites mediate idiosyncratic reactions associated with sulfonamides? Chem Res Toxicol 2003; 16:1035-43.
10. O'Neil CE, Reed MA, Lopez M, Hyslop N, Gutierrez E, Salvaggio J. Evaluation of immune parameters in HIV+ subjects reporting adverse reactions to sulfamethoxazole. Int Arch Allergy Appl Immunol 1991; 94:246-7.
11. Meekins CV, Sullivan TJ, Gruchalla RS. Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 1994; 94:1017-24.
12. Daftarian MP, Filion LG, Cameron W et al. Immune response to sulfamethoxazole in patients with AIDS. Clin Diagn Lab Immunol 1995; 2:199-204.
13. Gruchalla R, Pesenko R, Do T, Skiest D. Sulfonamide-induced reactions in desensitized patients with AIDS - the role of covalent protein haptenization by sulfamethoxazole. J Allergy Clin Immunol 1998; 101:371-8.
14. Lavergne SN, Volkman EM, Maki JE, Yoder AR, Trepanier LA. Evaluation of the clinical, immunologic, and biochemical effects of nitroso sulfamethoxazole administration to dogs: a pilot study. Toxicology 2005; 208:63-72.
15. Gruchalla RS, Sullivan TJ. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine. J Allergy Clin Immunol 1991; 88:784-92.
16. Naisbitt D, Farrell J, Gordon S et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002; 62:628-37.
17. Manchanda T, Hess D, Dale L, Ferguson S, Rieder M. Haptenization of sulfonamide reactive metabolites to cellular proteins. Mol Pharmacol 2002; 62:1011-26.
18. Naisbitt D, Gordon S, Pirmohamed M, Burkhart C, Cribb A, Pichler W et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenization and T-cell proliferation in vivo. Br J Pharmacol 2001; 133:295-305.
19. Gill HJ, Hough SJ, Naisbitt DJ, Maggs JL, Kitteringham NR, Pirmohamed M et al. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J Pharmacol Exp Therap 1997; 282:795-801.
20. Naisbitt DJ, Hough SJ, Gill HJ, Pirmohamed M, Kitteringham NR, Park BK. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999; 126:1393-407.
21. Bedard K, Smith S, Cribb A. Sequential assessment of an antidrug antibody response in a patient with a systemic delayed-onset sulphonamide hypersensitivity syndrome reaction. Br J Dermatol 2000; 142:253-8.
22. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23:483-507.
23. Farrell J, Naisbitt D, Drummond N, Depta J, Vilar F, Pirmohamed M et al. Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell repsonses in animal and humans. J Pharmacol Exp Therap 2003; 306:229-37.
24. Cribb A, Nuss C, Alberts D, Lamphere D, Grant D, Grossman S et al. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 1996; 9:500-7.
25. Nassif A, Bensussan A, Dorothee G, Mami-Chouaib F, Bachot N, Bagot M et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118:728-33.
26. Mauri-Hellweg, Bettens F, Mauri D, Brander C, Hunziker T, Pichler W. Activation of drug-specific CD4+ and CD8+T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155:462-72.
27. O'Hear CE, Foote J. Antibody buffering of a ligand in vivo. Proc Natl Acad Sci USA 2005; 102:40-4.
28. Rehlaender BN, Cho MJ. Anti-drug antibodies as drug carriers. I. For small molecules. Pharm Res 2001; 18:745-52.
29. Getahun A, Dahlstrom J, Wernersson S, Heyman B. IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc gamma receptors. J Immunol 2004; 172:5269-76.
30. de Valliere S, Abate G, Blazevic A, Heuertz RM, Hoft DF. Enhancement of innate and cell-mediated immunity by anti-mycobacterial antibodies. Infect Immun 2005; 73:6711-20.
31. Curtis B, McFarland J, Wu G-G, Visentin G, Aster R. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein Hb/IIIa complex. Blood 1994; 84:176-83.
32. Cribb AE, Pohl LR, Spielberg SP, Leeder JS. Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulumproteins. J Pharmacol Exp Thercs 1997; 282:1064-72.
33. Cimo PL, Pisciotta AV, Desai RG, Pino JL, Aster RH. Detection of drug-dependent antibodies by the 51Cr platelet lysis test: documentation of immune thrombocytopenia induced by diphenylhydantoin, diazepam, and sulfisoxazole. Am J Hematol 1977; 2:65-72.
34. Hensen EJ, Claas FH, Vermeer BJ. Drug-dependent binding of circulating antibodies in drug-induced toxic epidermal necrolysis. Lancet 1981; 2:151-2.
35. Huang JL, Hung IJ, Chen LC, Lee WY, Hsueh C, Hsieh KH. Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin. Clin Rheumatol 1998; 17:349-52.
36. Herrington A, Mahmood A, Berger R. Treatment options in sulfamethoxazole-trimethoprim-induced thrombocytopenic purpura. South Med J 1994; 87:948-50.
37. Chute JP, Frame JN, Ganey JT, Phares JC, Shakir KM. Intravenous immunoglobulin followed by platelet transfusion in the acute treatment of trimethoprim/sulfamethoxazole-induced immune thrombocytopenia. Am J Hematol 1993; 43:329-30.
38. Trepanier LA, Ray K, Winand N, Spielberg SP, Cribb AE. Cytosolic arylamine N-acetyltransferase deficiency in the dog and other canids due to an absence of NAT genes. Biochem Pharmacol 1997; 54:73-80.
39. Relling M. Polymorphic drug metabolism. Clin Pharm 1989; 8:852-63.
40. Cribb AE, Spielberg SP, Griffin GP. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995; 23:406-14.
41. Cribb A, Miller M, Tesoro A, Spielberg S. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol Pharmacol 1990; 38:744-51.
42. Naisbitt D, O'Neill P, Pirmohamed M, Park B. Synthesis and reactions of nitroso sulphamethoxazole with biological nucleophiles: implications for immune mediated toxicity. Bioorg Med Chemy Lett 1996; 6:1511-6.
43. Trepanier L, Yoder A, Bajad S, Beckwith M, Bellehumeur J, Graziano F. Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole-nitroso in HIV infection. J Acquir Immune Defic Syndr 2004; 36:1041-50.
44. Trepanier L, Miller J. NADH-dependent reduction of sulphamethoxazole hydroxylamine in dog and human liver microsomes. Xenobiotica 2000; 30:1111-21.
45. 5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther 2004; 311:1171-8.